These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
840 related articles for article (PubMed ID: 15813652)
1. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? Savage R Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652 [TBL] [Abstract][Full Text] [Related]
2. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261 [TBL] [Abstract][Full Text] [Related]
3. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
4. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215 [TBL] [Abstract][Full Text] [Related]
5. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]. Blain H; Jouzeau JY; Netter P; Jeandel C Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595 [TBL] [Abstract][Full Text] [Related]
6. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
7. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Matheson AJ; Figgitt DP Drugs; 2001; 61(6):833-65. PubMed ID: 11398914 [TBL] [Abstract][Full Text] [Related]
8. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
9. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Weir MR; Sperling RS; Reicin A; Gertz BJ Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
11. Current perspective on the cardiovascular effects of coxibs. Konstam MA; Weir MR Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293 [TBL] [Abstract][Full Text] [Related]
12. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Harley C; Wagner S Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116 [TBL] [Abstract][Full Text] [Related]
13. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
14. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Goldenberg MM Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845 [TBL] [Abstract][Full Text] [Related]
15. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Strand V Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036 [TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors. Brooks PM; Day RO Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038 [TBL] [Abstract][Full Text] [Related]
17. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Hochberg MC Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of selective COX-2 inhibitors. Capone ML; Tacconelli S; Sciulli MG; Patrignani P Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704 [TBL] [Abstract][Full Text] [Related]
19. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Bennett K; Teeling M; Feely J Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226 [TBL] [Abstract][Full Text] [Related]
20. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Kean WF; Buchanan WW Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]